Symbio will be attending EAACI 2025 in Glasgow, United Kingdom, June 13-16.

Industry leaders will come together for this year’s premier event with an inspiring theme, “Breaking Boundaries in Allergy, Asthma, and Clinical Immunology: Integrating Planetary Health for a Sustainable Future”.

As a specialized Global CRO, Symbio is committed to advancing care in Allergy, Asthma and Immunology. With deep expertise in Dermatology, Inflammatory Disease, Aesthetics and Gastroenterology, we are excited to join global leaders advancing science and care in these critical areas.

Looking forward to connecting at EAACI and discussing how Symbio can accelerate progress with your clinical trials.

Patrick Ronan to Keynote on Trump-Era Healthcare Impacts

Symbio Board Member and former FDA Chief of Staff, Patrick Ronan will be a Keynote Speaker at the upcoming 16th Annual Outsourcing in Clinical Trials East Coast! “Trump Administration’s Effect on Healthcare Through the Lens of a Former Regulator”

🔹 Healthcare Themes under the Trump Administration
🔹 Update on Key Priorities and Opportunities
🔹 Short-and Long-term Effects of Staffing and Budget Cuts

Presenting: Tuesday, May 20, 12:30-1:00 pm

Symbio to Serve as Event Partner at the 6th Annual Dermatology Drug Development Summit

The Annual Dermatology Drug Development Summit is a premier industry forum that is focused on advancing next-generation immunodermatology therapies and brings together leaders and innovators from across the field. We look forward to engaging in insightful discussions, exploring groundbreaking ideas, and building meaningful collaborations with our peers.

Berlin, Germany
May 27-28, 2025

Symbio to Attend the 16th Annual Outsourcing in Clinical Trials East

Symbio is excited to be an exhibitor at the 16th Annual Outsourcing in Clinical Trials (OCT) East conference, taking place May 20-21 at the Valley Forge Casino Resort, King of Prussia, PA. This premier event brings together industry leaders, experts, and innovators in the clinical research field to discuss the latest trends, challenges, and opportunities in outsourcing for clinical trials.

We look forward to two days of insightful panel discussions, keynote presentations, and networking sessions, all designed to facilitate knowledge sharing and strategic partnerships.

As a trusted partner in the industry, we are committed to leveraging the latest advancements to enhance trial outcomes and streamline the development process.

Symbio Attends ACE 2025: Connecting with Industry Leaders in Aesthetics

Symbio was once again excited to attend the Aesthetic Conference & Exhibition (ACE) March 14 & 15, in London.  ACE is the UK’s leading non-surgical aesthetics event, bringing together leading pharmaceutical, device and skin care companies. Our colleague, Dr. David Bruce, attended the event, where he had the opportunity to meet representatives from dermal filler, exosome, medical device and cosmetic companies to better understand their business needs.

AAD 2025 – Thank You Orlando!

Symbio and Dow Development Labs, were excited and proud to once again exhibit at the annual American Academy of Dermatology (AAD) Meeting, held this year in Orlando, FL. The meeting gave us a fantastic opportunity to connect with industry professionals, sponsors and key opinion leaders, while discussing the latest developments and the future of dermatology.

We sincerely appreciate those who stopped by our booth to chat and those who took the time to meet with our team members.  As part of our AAD tradition, we once again hosted our Client Happy Hour on Friday evening at Universal CityWalk, NBC Sports Grill & Brew.  It is always a distinct pleasure and highlight for the Symbio team to host this annual event, providing an opportunity for engaging conversations and time to reconnect. A great time was had by all!

On Saturday evening, we hosted an exclusive event, welcoming partners, clients and investigators to an insightful talk, provided by our Board Member and former FDA Chief of Staff, Patrick Ronan.  Patrick shared his expertise on, “How the Trump Administration Will Impact Healthcare”, providing valuable perspective on the evolving regulatory landscape.

Thank you to everyone who made this year’s AAD meeting such a success – we look forward to seeing you again next year, in Denver, Colorado.

Aesthetics Tech Forum 2025

January 9th & 10th, New Port Beach, CA

Octane’s Aesthetics Tech Forum is the premier event for physicians, industry professionals, investors, and entrepreneurs in the aesthetics technology space.

The Forum brings together thought leaders and innovators to explore cutting-edge medical aesthetic technologies, identify unmet clinical needs, and uncover new business opportunities.

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Symbio is thrilled to announce and share the recent press release from Jasper Therapeutics. We are incredibly proud to have been the CRO partner for this successful study. This achievement marks a significant milestone in our collaboration and commitment to advancing innovative therapies for the treatment of Urticaria and other mast cell-mediated diseases. Read full press release, “Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria”.

 

 

 

Symbio, Global Clinical Research Organization, Announces Two Key Leadership Appointments

January 13, 2025, New York, NY and Munster, Germany: Symbio, the global specialist therapeutic clinical research organization, is pleased to announce two key leadership appointments.

Shanna Smith is appointed Chief Commercial Officer. Shanna has a 16-year tenure with Symbio and brings an extensive background in crafting customer solutions in both clinical operations and commercial functions. She has played a pivotal role in driving Symbio’s growth and commitment to quality, building outstanding relationships with clients and investigators, and expanding Symbio’s global presence.

Patrick Ronan is appointed to the Board of Directors of Symbio. Patrick currently serves as an Operating Partner at ARCHIMED, a global investment firm focused on the healthcare industries. He is the former CEO of two life sciences firms, Validant (now Eliquent Life Sciences) and Greenleaf Health, which he founded in 2007. Prior to this, Patrick served as VP Regulatory Policy & External Affairs at Novartis and before that as Chief of Staff at the U.S. Food and Drug Administration (FDA), an executive role where he led the Agency on strategic, operational, and regulatory policy matters.

In a joint statement, Alan Morgan, Chief Executive, and Nick Thornton, Chairman said, “The high caliber of these appointments reflects Symbio’s commitment to bringing the highest levels of expertise to our clients’ development programs. We congratulate Shanna and Patrick and wish them much success and enjoyment in their new roles.”

 

Press queries contact:
Rose Panico, Symbio Director of Global Marketing
Office: +1-631-474-8531
Mobile: +1-516-994-6683
rose.panico@symbioresearch.com
symbioresearch.com

About Symbio

Symbio is a global specialist therapeutic CRO with exceptional expertise in Dermatology, Aesthetics, Wound Care, Ophthalmology, Inflammation, and Gastroenterology. The business operates across the USA and Europe, with additional expertise in Latin America, and Asia.